FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912056231> ?p ?o ?g. }

• W2912056231 endingPage "e023600" @default.
• W2912056231 startingPage "e023600" @default.
• W2912056231 abstract "Objective To assess the benefits and harms of pregabalin in the management of neuropathic pain. Design Rapid review and meta-analysis of phase III, randomised, placebo-controlled trials. Participants Adults aged 18 years and above with neuropathic pain defined according to the International Association for the Study of Pain criteria. Interventions Pregabalin or placebo. Primary and secondary outcome measures Our primary outcomes were pain (as measured using validated scales) and adverse events. Our secondary outcomes were sleep disturbance, quality of life, Patient Global Impression of Change, Clinician Global Impression scale, anxiety and depression scores, overall discontinuations and discontinuations because of adverse events. Results We included 28 trials comprising 6087 participants. The neuropathic pain conditions studied were diabetic peripheral neuropathy, postherpetic neuralgia, herpes zoster, sciatica (radicular pain), poststroke pain and spinal cord injury-related pain. Patients who took pregabalin reported significant reductions in pain (numerical rating scale (NRS)) compared with placebo (standardised mean difference (SMD) −0.49 (95% CI −0.66 to −0.32, p<0.00001), very low quality evidence). Pregabalin significantly reduced sleep interference scores (NRS) compared with placebo (SMD −0.38 (95% CI −0.50 to −0.26, p<0.00001), moderate quality evidence. Pregabalin significantly increased the risk of adverse events compared with placebo (RR 1.33 (95% CI 1.23 to 1.44, p<0.00001, low quality evidence)). The risks of experiencing weight gain, somnolence, dizziness, peripheral oedema, fatigue, visual disturbances, ataxia, non-peripheral oedema, vertigo and euphoria were significantly increased with pregabalin. Pregabalin was significantly more likely than placebo to lead to discontinuation of the drug because of adverse events (RR 1.91 (95% CI 1.54 to 2.37, p<0.00001), low quality evidence). Conclusion Pregabalin has beneficial effects on some symptoms of neuropathic pain. However, its use significantly increases the risk of a number of adverse events and discontinuation due to adverse events. The quality of the evidence from journal publications is low." @default.
• W2912056231 created "2019-02-21" @default.
• W2912056231 creator A5027878704 @default.
• W2912056231 creator A5027970978 @default.
• W2912056231 creator A5033917119 @default.
• W2912056231 creator A5054757405 @default.
• W2912056231 creator A5062680588 @default.
• W2912056231 date "2019-01-01" @default.
• W2912056231 modified "2023-10-14" @default.
• W2912056231 title "Benefits and harms of pregabalin in the management of neuropathic pain: a rapid review and meta-analysis of randomised clinical trials" @default.
• W2912056231 cites W1247968195 @default.
• W2912056231 cites W1496322206 @default.
• W2912056231 cites W1665446506 @default.
• W2912056231 cites W1714980748 @default.
• W2912056231 cites W1845521331 @default.
• W2912056231 cites W1964162160 @default.
• W2912056231 cites W1965579959 @default.
• W2912056231 cites W1965724497 @default.
• W2912056231 cites W1965909044 @default.
• W2912056231 cites W1972387365 @default.
• W2912056231 cites W1996715799 @default.
• W2912056231 cites W1999935589 @default.
• W2912056231 cites W2001322197 @default.
• W2912056231 cites W2011913908 @default.
• W2912056231 cites W2020407769 @default.
• W2912056231 cites W2028295001 @default.
• W2912056231 cites W2038826804 @default.
• W2912056231 cites W2047744167 @default.
• W2912056231 cites W2048776101 @default.
• W2912056231 cites W2049689960 @default.
• W2912056231 cites W2051600052 @default.
• W2912056231 cites W2054260401 @default.
• W2912056231 cites W2062147413 @default.
• W2912056231 cites W2063925605 @default.
• W2912056231 cites W2068602147 @default.
• W2912056231 cites W2068757724 @default.
• W2912056231 cites W2070246197 @default.
• W2912056231 cites W2076716839 @default.
• W2912056231 cites W2080477042 @default.
• W2912056231 cites W2085427610 @default.
• W2912056231 cites W2092255211 @default.
• W2912056231 cites W2094822188 @default.
• W2912056231 cites W2098923148 @default.
• W2912056231 cites W2099304023 @default.
• W2912056231 cites W2104818454 @default.
• W2912056231 cites W2120306614 @default.
• W2912056231 cites W2125761169 @default.
• W2912056231 cites W2128412489 @default.
• W2912056231 cites W2136415182 @default.
• W2912056231 cites W2152802140 @default.
• W2912056231 cites W2158523533 @default.
• W2912056231 cites W2159977024 @default.
• W2912056231 cites W2164005268 @default.
• W2912056231 cites W2168488550 @default.
• W2912056231 cites W2168784208 @default.
• W2912056231 cites W2198206933 @default.
• W2912056231 cites W2206489433 @default.
• W2912056231 cites W2522925890 @default.
• W2912056231 cites W2528576656 @default.
• W2912056231 cites W2586562815 @default.
• W2912056231 cites W2588681363 @default.
• W2912056231 cites W2600085695 @default.
• W2912056231 cites W2614093955 @default.
• W2912056231 cites W2735482093 @default.
• W2912056231 cites W2740244424 @default.
• W2912056231 cites W2757526067 @default.
• W2912056231 cites W2777106557 @default.
• W2912056231 cites W2794797808 @default.
• W2912056231 doi "https://doi.org/10.1136/bmjopen-2018-023600" @default.
• W2912056231 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6347863" @default.
• W2912056231 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30670513" @default.
• W2912056231 hasPublicationYear "2019" @default.
• W2912056231 type Work @default.
• W2912056231 sameAs 2912056231 @default.
• W2912056231 citedByCount "57" @default.
• W2912056231 countsByYear W29120562312019 @default.
• W2912056231 countsByYear W29120562312020 @default.
• W2912056231 countsByYear W29120562312021 @default.
• W2912056231 countsByYear W29120562312022 @default.
• W2912056231 countsByYear W29120562312023 @default.
• W2912056231 crossrefType "journal-article" @default.
• W2912056231 hasAuthorship W2912056231A5027878704 @default.
• W2912056231 hasAuthorship W2912056231A5027970978 @default.
• W2912056231 hasAuthorship W2912056231A5033917119 @default.
• W2912056231 hasAuthorship W2912056231A5054757405 @default.
• W2912056231 hasAuthorship W2912056231A5062680588 @default.
• W2912056231 hasBestOaLocation W29120562311 @default.
• W2912056231 hasConcept C126322002 @default.
• W2912056231 hasConcept C142724271 @default.
• W2912056231 hasConcept C168563851 @default.
• W2912056231 hasConcept C1862650 @default.
• W2912056231 hasConcept C197934379 @default.
• W2912056231 hasConcept C204787440 @default.
• W2912056231 hasConcept C27081682 @default.
• W2912056231 hasConcept C2776468701 @default.
• W2912056231 hasConcept C2776608144 @default.
• W2912056231 hasConcept C2776698514 @default.
• W2912056231 hasConcept C2777107010 @default.

• next